Nasal decongestants in monotherapy for the common cold

Deckx, Laura; Sutter, An IM De; Guo, Linda; Mir, Nabiel; Driel, Mieke van

doi:10.1002/14651858.cd009612.pub2

Cited by 79 publications

(62 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Over-the-counter antihistamines are commonly used to relieve symptoms but have a short-term beneficial effect and do not appear to be effective in children [48]. Over-the-counter nasal decongestants are also used, although their effectiveness and safety in children and the clinical relevance of their small symptomatic effect in adults have yet to be demonstrated [49]. Furthermore, the available evidence does not support the use of intranasal corticosteroids for symptomatic relief from the common cold [50].…”

Section: Discussionmentioning

confidence: 99%

A marine-sourced fucoidan solution inhibits Toll-like-receptor-3-induced cytokine release by human bronchial epithelial cells

Dutot

Grassin-Delyle

Salvator

et al. 2019

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Fucoidans are sulfated polysaccharides from brown algae, known to have immunomodulatory activity. Their effects on the response of airway epithelial cells to Toll-like receptor 3 (TLR3) stimulation have not been characterized. Our objective was to evaluate the effects of a marine-sourced fucoidan solution (MFS) on the TLR3-induced expression and/or production of cytokines and prostaglandin by human primary bronchial epithelial cells as a model of the airway epithelium. The cells were incubated with MFS in the presence or absence of Poly(I:C) (a TLR3 agonist that mimics viral RNA). Cytokine expression and production were assessed using RT-qPCR and ELISA. The expression of cyclooxygenase-2 and the production of prostaglandin E2 were also measured. Relative to control, exposure to MFS was associated with lower Poly(I:C)-induced mRNA expression of various cytokines and chemokines, and lower COX-2 production. The MFS inhibited the production of some cytokines (IL-1α, IL-1β, TNFα, and IL-6), chemokines (CCL5, CCL22, CXCL1, CXCL5 and CXCL8) and prostaglandin E2 but did not alter the production of IL-12/25, CCL2 and CCL20. At clinically relevant concentrations, the MFS inhibited the TLR3mediated production of inflammatory mediators by human primary bronchial epithelial cells -suggesting that locally applied MFS might help to reduce airway inflammation in viral infections.

show abstract

Section: Discussionmentioning

confidence: 99%

A marine-sourced fucoidan solution inhibits Toll-like-receptor-3-induced cytokine release by human bronchial epithelial cells

Dutot

Grassin-Delyle

Salvator

et al. 2019

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

show abstract

“…No existe evidencia que apoye el uso de oximetazolina (un agonista alfa-1 y agonista parcial alfa-2) como descongestionante nasal para la optimización preoperatoria de pacientes con IVRS que requieren anestesia general. Deckx et al (31), en su revisión sistemática, no determinan la eficacia y perfil de seguridad de los descongestionantes nasales, incluyendo la oximetazolina, en población pediátrica.…”

Section: Oximetazolinaunclassified

Manejo perioperatorio de niños con infección respiratoria superior

et al. 2019

View full text Add to dashboard Cite

ARTÍCULO DE REVISIÓN| Resumen | Introducción. Es frecuente que muchos niños sometidos a procedimientos con anestesia general tengan historia de infección viral respiratoria superior reciente o activa.Objetivo. Realizar una revisión narrativa acerca de las pautas de manejo anestésico para los niños con infección reciente o activa de la vía aérea superior. Materiales y métodos.Se realizó una búsqueda estructurada de la literatura en las bases de datos ProQuest, Laryngospasm OR Bronchospasm. La búsqueda se hizo en inglés con sus equivalentes en español.Resultados. Se encontraron 56 artículos con información relevante para el desarrollo de la presente revisión.Conclusiones. Una menor manipulación de la vía aérea tiende a disminuir la frecuencia de aparición y severidad de eventos adversos respiratorios perioperatorios. No existe evidencia suficiente para recomendar la optimización medicamentosa en pacientes con infección respiratoria superior.Palabras clave: Anestesia general; Infecciones del sistema respiratorio; Laringismo; Espasmo bronquial (DeCS). Corrales-Zúñiga NC, Martínez-Muñoz NP, Realpe-Cisneros SI, Pacichana-Agudelo CE, Realpe-Cisneros LG, Cerón-Bastidas JA, et al. Manejo perioperatorio de niños con infección respiratoria superior. Rev. Fac. Med. 2019;67(2):341-7. Spanish. doi: http://dx.doi.org/10.15446/revfacmed.v67n2.66540. | Abstract | Introduction: History of recent or active upper respiratory tract infection is common in many children undergoing general anesthesia procedures. Objective: To conduct a narrative review of anesthetic management guidelines for children with recent or active upper respiratory tract infection.Results: 56 articles had information relevant to meet the objective of this review. Conclusions:Minimizing manipulation of the airway tends to decrease the frequency and severity of perioperative adverse respiratory events. There is not sufficient evidence to recommend drug optimization in patients with upper respiratory tract infection. Corrales-Zúñiga NC, Martínez-Muñoz NP, Realpe-Cisneros SI, Pacichana-Agudelo CE, Realpe-Cisneros LG, Cerón-Bastidas JA, et al. [Perioperative management of children with upper respiratory tract infection]. Rev. Fac. Med. 2019;67(2):341-7. Spanish. doi: http://dx.doi.org/10.15446/revfacmed.v67n2.66540.

show abstract

“…A patient with uncomplicated nasal symptoms for less than 7 days should be managed as a common cold as assessed and reported in different Cochrane reviews (35)(36)(37)(38) . Evaluation of the presence of allergy should be considered when a patient repeatedly consults with ARS (5) .…”

Section: Strengths Of the Current Pathwaysmentioning

confidence: 99%

EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis

2017

Rhin

View full text Add to dashboard Cite

The first European Rhinology Research Forum organized by the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) was held in the Royal Academy of Medicine in Brussels on 17th and 18th November 2016, in collaboration with the European Rhinologic Society (ERS) and the Global Allergy and Asthma European Network (GA2LEN). One hundred and thirty participants (medical doctors from different specialties, researchers, as well as patients and industry representatives) from 27 countries took part in the multiple perspective discussions including brainstorming sessions on care pathways and research needs in rhinitis and rhinosinusitis. The debates started with an overview of the current state of the art, including weaknesses and strengths of the current practices, followed by the identification of essential research needs, thoroughly integrated in the context of Precision Medicine (PM), with personalized care, prediction of success of treatment, participation of the patient and prevention of disease as key principles for improving current clinical practices. This report provides a concise summary of the outcomes of the brainstorming sessions of the European Rhinology Research Forum 2016.

show abstract

Nasal decongestants in monotherapy for the common cold

Cited by 79 publications

References 44 publications

A marine-sourced fucoidan solution inhibits Toll-like-receptor-3-induced cytokine release by human bronchial epithelial cells

A marine-sourced fucoidan solution inhibits Toll-like-receptor-3-induced cytokine release by human bronchial epithelial cells

Manejo perioperatorio de niños con infección respiratoria superior

EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis

Contact Info

Product

Resources

About